Susquehanna International Group
AVDL

Susquehanna International Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Susquehanna International Group’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,714,600
Closed -$36.9M – 13141
2025
Q4 		$36.9M Buy
1,714,600
+140,800
+9% +$2.73M ﹤0.01% 1621
2025
Q3 		$24M Buy
1,573,800
+1,533,000
+3,757% +$19.9M ﹤0.01% 2011
2025
Q2 		$361K Sell
40,800
-10,300
-20% -$90.5K ﹤0.01% 9920
2025
Q1 		$400K Sell
51,100
-435,700
-90% -$3.65M ﹤0.01% 9397
2024
Q4 		$5.12M Sell
486,800
-462,100
-49% -$5.61M ﹤0.01% 3550
2024
Q3 		$12.4M Buy
948,900
+286,300
+43% +$4.36M ﹤0.01% 2338
2024
Q2 		$9.32M Buy
662,600
+11,000
+2% +$179K ﹤0.01% 2581
2024
Q1 		$11M Buy
651,600
+247,000
+61% +$3.68M ﹤0.01% 2473
2023
Q4 		$5.71M Buy
404,600
+86,200
+27% +$1.01M ﹤0.01% 3482
2023
Q3 		$3.28M Sell
318,400
-93,100
-23% -$1.25M ﹤0.01% 4228
2023
Q2 		$6.78M Buy
411,500
+98,300
+31% +$1.28M ﹤0.01% 3042
2023
Q1 		$2.87M Sell
313,200
-158,300
-34% -$1.3M ﹤0.01% 4422
2022
Q4 		$3.38M Buy
471,500
+200,300
+74% +$1.4M ﹤0.01% 3831
2022
Q3 		$1.36M Sell
271,200
-493,900
-65% -$2.72M ﹤0.01% 5837
2022
Q2 		$1.87M Buy
765,100
+560,500
+274% +$2.3M ﹤0.01% 5060
2022
Q1 		$1.4M Sell
204,600
-2,500
-1% -$17.2K ﹤0.01% 6316
2021
Q4 		$1.67M Sell
207,100
-156,600
-43% -$1.43M ﹤0.01% 5944
2021
Q3 		$3.56M Buy
363,700
+43,500
+14% +$343K ﹤0.01% 4596
2021
Q2 		$2.15M Buy
320,200
+144,300
+82% +$1.15M ﹤0.01% 5746
2021
Q1 		$1.59M Buy
175,900
+115,800
+193% +$936K ﹤0.01% 6483
2020
Q4 		$401K Buy
60,100
+48,400
+414% +$303K ﹤0.01% 8723
2020
Q3 		$59K Sell
11,700
-169,400
-94% -$1.23M ﹤0.01% 10154
2020
Q2 		$1.46M Sell
181,100
-226,800
-56% -$2M ﹤0.01% 5080
2020
Q1 		$3.24M Buy
407,900
+334,000
+452% +$2.57M ﹤0.01% 3166
2019
Q4 		$558K Buy
73,900
+58,000
+365% +$306K ﹤0.01% 6768
2019
Q3 		$66K Buy
+15,900
New +$39.8K ﹤0.01% 9704
2018
Q4 		– Sell
-16,900
Closed -$74K – 8900
2018
Q3 		$74K Sell
16,900
-10,300
-38% -$55.6K ﹤0.01% 8712
2018
Q2 		$167K Buy
27,200
+12,400
+84% +$87K ﹤0.01% 8772
2018
Q1 		$108K Buy
+14,800
New +$130K ﹤0.01% 8664
2017
Q2 		– Sell
-13,500
Closed -$131K – 9165
2017
Q1 		$131K Buy
+13,500
New +$135K ﹤0.01% 8266
2016
Q2 		– Sell
-11,500
Closed -$127K – 8515
2016
Q1 		$127K Sell
11,500
-61,700
-84% -$613K ﹤0.01% 8318
2015
Q4 		$894K Buy
73,200
+49,700
+211% +$775K ﹤0.01% 5636
2015
Q3 		$383K Sell
23,500
-89,000
-79% -$1.96M ﹤0.01% 7619
2015
Q2 		$2.38M Buy
112,500
+29,600
+36% +$531K ﹤0.01% 4338
2015
Q1 		$1.49M Buy
82,900
+48,100
+138% +$753K ﹤0.01% 4928
2014
Q4 		$596K Sell
34,800
-35,900
-51% -$513K ﹤0.01% 6892
2014
Q3 		$1.01M Buy
70,700
+35,500
+101% +$510K ﹤0.01% 5899
2014
Q2 		$528K Buy
35,200
+20,800
+144% +$251K ﹤0.01% 7361
2014
Q1 		$193K Buy
+14,400
New +$154K ﹤0.01% 8264
2013
Q3 		– Sell
-15,700
Closed -$97K – 8373
2013
Q2 		$97K Buy
+15,700
New +$81.1K ﹤0.01% 7789

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Susquehanna International Group's AVDL Position: Q1 2026 in Review

Susquehanna International Group sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 61,690 shares — an estimated $1.33M sold.

Susquehanna International Group first reported a position in AVDL in Q2 2013 and held it in 41 quarters. The position peaked at $4.61M in Q2 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Susquehanna International Group reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 61,690 Avadel Pharmaceuticals shares in Q1 2026, an estimated $1.33M.
  • Susquehanna International Group first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 41 quarters.
  • Susquehanna International Group's Avadel Pharmaceuticals position peaked at $4.61M in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.